ARID1A and gastric cancer: Thus, the discovery of a link between ARID1A deletion and the profile of immunotherapy biomarkers (PD-L1, TMB, MMR, and TILs) in GC suggests the possible role of ARID1A deletion as a predictive biomarker for responses to immunotherapy.